Please login to the form below

Not currently logged in
Email:
Password:

Liponova signs MOU for renal cancer vaccine

LipoNova signs a Memorandum of Understanding for the development and marketing of its non-metastatic renal cell carcinoma candidate vaccine Reniale with an unnamed non-European partner

German biopharmaceutical and vaccines company LipoNova has signed a Memorandum of Understanding (MoU) for the development and marketing of its non-metastatic renal cell carcinoma (RCC) candidate vaccine Reniale with an as yet unnamed non-European pharmaceutical company.

The MoU provides for milestone payments and ongoing royalties on sales of Reniale. LipoNova's partner will win an exclusive licence for marketing the product to a non-European country. The partner will, on conclusion of the agreement, support an international phase III study and be involved in possible 'named patients' programmes.

Liponova's executive board says the MoU is an important step in the development and marketing of Reniale outside Europe. The deal shows that foreign companies are very interested in marketing Reniale and therefore provides further evidence or Reniale's market potential. The company added that it aimed to launch Reniale on other non-European markets.

For H1 2007, Liponova made a loss of EUR 2.3m, compared with a loss of just under EUR 1m in H1 FY06. The increased loss was due to extra consultancy costs incurred in 2007 over preparations for the Reniale phase III study, while the company is still not making any significant sales.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics